注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Cyclacel Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司致力于开发基于细胞周期、转录调控和有丝分裂控制生物学的癌症药物。该公司专注于癌症细胞周期生物学领域,其愿景是通过将癌症生物学的见解转化为能够克服耐药性并最终提高患者总体生存率的药物来改善患者医疗保健。该公司的生产线包括Fadraciclib、CYC140和Sapacitabine。Fadraciclib是一种选择性靶向细胞周期蛋白依赖性激酶2(CDK2)和细胞周期蛋白依赖性激酶9(CDK9)的细胞周期蛋白依赖性激酶(CDK)抑制剂。CYC140是一种新型、小分子、选择性和有效的PLK中心抑制剂。该公司的Sapacitabine(CYC682)是一种口服核苷类似物,具有DNA损伤反应(DDR)机制。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Spiro George Rombotis | 62 | 1997 | President, CEO & Executive Director |
Christopher S. Henney | 80 | 2006 | Independent Chairman |
Robert Jay Spiegel | 72 | 2018 | Independent Vice Chairman |
Paul McBarron | 61 | 2006 | Executive VP of Finance, CFO, COO, Secretary & Executive Director |
Kenneth M. Ferguson | 67 | 2022 | Independent Director |
Kenneth R. Harrap | - | - | Member of Scientific Advisory Board |
Michel E. Marty | - | - | Member of Scientific Advisory Board |
Edward Karol Sikora | 74 | - | Member of Scientific Advisory Board |
Stanley B. Kaye | - | - | Member of Scientific Advisory Board |
Samuel L. Barker | 81 | 2014 | Independent Director |
Karin L. Walker | 61 | 2020 | Independent Director |
Brian Schwartz | 62 | 2020 | Interim Chief Medical Officer & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核